Eli Lilly and Company LLY reported third-quarter 2026 adjusted earnings per share ("EPS") of $7.48, which beat the Zacks Consensus Estimate of $5.38 per share by 39.0%. Earnings rose 7% year over year. Revenues of $24.40 billion rose 39% year over year, driven by robust volume growth of Lilly's popular GLP-1 drugs, Mounjaro and Zepbound. Newer products also contributed to growth. One-time benefits, including $410 million of Jardiance milestones and favorable U.S. rebate/discount estimate adjustments, also benefited sales in the third quarter. Total revenues beat the Zacks Consensus Estimate of $22.11 billion by 10.4%. While U.S. revenues rose 34% to $15.1 billion, ex-U.S. revenues increased 47% to $9.3 billion.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.